---
layout: default
title: Bupivacaine
parent: 僅模型預測 (L5)
nav_order: 63
evidence_level: L5
indication_count: 4
---

# Bupivacaine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **4** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Bupivacaine: From Local Anesthesia to Acrodermatitis Chronica Atrophicans

## One-Sentence Summary

> Bupivacaine is a well-known local anesthetic/analgesic agent (voltage-gated sodium channel blocker), though its Norway-approved indication text is not present in this evidence pack.
> The TxGNN model predicts it may be effective for **Acrodermatitis Chronica Atrophicans**, a late-stage skin manifestation of Lyme disease,
> but **no clinical trials** and **no publications** currently support this direction — the model's own rationale flags the mechanistic link as unsupported.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in registry data (drug class per evidence pack: local anesthesia/regional analgesia); no Norway-approved indication text available |
| Predicted New Indication | Acrodermatitis Chronica Atrophicans |
| TxGNN Prediction Score | 99.23% |
| Evidence Level | L5 |
| Norway Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in structured form (original_moa is flagged as a data gap). Based on the rationale text accompanying this prediction, Bupivacaine is a voltage-gated sodium channel blocker whose known pharmacological effect is local anesthesia/analgesia.

Acrodermatitis chronica atrophicans is a chronic, atrophic skin manifestation of late-stage Lyme disease (Borrelia infection), pathologically driven by chronic spirochetal infection, immune response, and abnormal collagen metabolism. There is no known pharmacological overlap between sodium-channel blockade (Bupivacaine's mechanism) and the infectious/immune/fibrotic pathways underlying this condition.

The evidence pack's own rationale explicitly states that this high TxGNN score likely reflects an indirect knowledge-graph association (e.g., co-occurrence with other dermatology drugs) rather than a genuine mechanistic link. No direct pharmacological rationale supports this repurposing hypothesis.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Norway Market Information

Currently no marketed authorizations in Norway (market status: Not Marketed; 0 licenses on record)

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
There is no clinical or literature evidence supporting this indication, and the evidence pack's own mechanistic analysis flags the predicted association as lacking pharmacological plausibility (likely a knowledge-graph co-occurrence artifact). The drug is also not currently marketed in Norway, and safety documentation is incomplete.

**To proceed, the following is needed:**
- TFDA/Norway product label warnings and contraindications (blocking data gap — required before any S1 safety review)
- Confirmed original mechanism of action and approved indication text (currently a data gap)
- Preclinical or mechanistic studies establishing a plausible biological link to acrodermatitis chronica atrophicans before further evaluation
- Re-screening of lower-ranked candidates (neonatal dermatomyositis, secondary ILD in childhood connective tissue disease, amyopathic dermatomyositis) — all similarly lack mechanistic or evidentiary support and carry the same Hold recommendation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

